AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Corporate Update (November 2018)

21 slides from AVEO Pharmaceuticals's corporate update, Nov 5, 2018

  1. Slide 1: TIVO-3 Phase 3 Pivotal Trial of Tivozanib Meets Primary Endpoint

    TIVO-3: Phase 3 Pivotal Trial of Tivozanib Meets Primary Endpoint of Improving Progression Free Survival in Renal Cell Carcinoma Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”

  3. Slide 3: AVEO Oncology Introduction

    AVEO Oncology Introduction Matt Dallas, CFO Opening Remarks Michael Bailey, President and CEO TIVO-3 Highlights Michael Needle, M.D., CMO Closing Michael Bailey, President and CEO Joining for Q&A Matt Dallas, CFO Michael Bailey, President and CEO Michael Needle, M.D., CMO Michael Ferraresso, VP of A

  4. Slide 4: Opening Remarks

    Opening Remarks Michael Bailey, President and Chief Executive Officer

  5. Slide 5: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71

  6. Slide 6: Positive Results for TIVO-3

    Positive Results for TIVO-3 Tivozanib: distinct among VEGF TKIs, providing both improved efficacy AND favorable tolerability TIVO-1: Phase 3 H2H study in 1st line RCC demonstrating superiority on primary PFS endpoint vs VEGF TKI TIVO-3: first and only Phase 3 study in third and fourth line RCC to sh

  7. Slide 7: Thank You!

    Thank You! Patients and their families Healthcare professionals Advisors and supporters AVEO employees and board

  8. Slide 8: Opening Remarks

    Opening Remarks Michael Needle, M.D., Chief Medical Officer

  9. Slide 9: Large and Growing Patient Population

    Large and Growing Patient Population One of top ten most commonly diagnosed cancers Diagnoses (U.S.) 60,000 Deaths (U.S.) ~15,000 5-year Survival 12% Available therapies VEGF inhibitors Immunotherapies mTOR inhibitors Source: American Cancer Society

  10. Slide 10: TIVO-3: First Successful Third and Fourth-line Phase 3 Study in RCC

    TIVO-3: First Successful Third and Fourth-line Phase 3 Study in RCC N = 351 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety an

  11. Slide 11: Primary Endpoint – Final Analysis: Superior Progression Free Survival

    Primary Endpoint – Final Analysis Superior Progression Free Survival HR (95%CI)=0.74 (0.57,0.96) Median PFS: Tivozanib 5.59 (5.29,7.33) mo Sorafenib 3.91 (3.71,5.55) mo

  12. Slide 12: Secondary Endpoint – Preliminary Analysis: Overall Survival

    Secondary Endpoint – Preliminary Analysis Overall Survival Not Mature at Time of Final PFS Analysis At the time of the preliminary OS analysis, no statistically significant difference was observed (HR=1.06, p=0.69) Both arms far exceed benchmarks for 3rd and 4th line Considerations at the time of pr

  13. Slide 13: Preliminary OS in Context

    Preliminary OS in Context Axitinib Pivotal Study in RCC HR=1.070 HR=1.008 Source: ODAC briefing document October 2011 “The analysis of OS was not mature at the time of the final PFS analysis with the median follow-up in each arm of approximately 11 months and only 50% of the total number of required

  14. Slide 14: Secondary Endpoint – Final Analysis: Superior Overall Response Rate

    Secondary Endpoint – Final Analysis Superior Overall Response Rate p=0.02 18% 8% sorafenib tivozanib

  15. Slide 15: TIVO-3: Safety

    TIVO-3: Safety Tivozanib was generally well-tolerated Patients on the tivozanib arm received 95% of the targeted dose compared to 75% for sorafenib Grade 3 or higher adverse events consistent with those observed in previous tivozanib trials Infrequent but severe adverse events reported in greater nu

  16. Slide 16: Regulatory Update

    Regulatory Update Goal to submit a New Drug Application to the U.S. Food and Drug Administration in ~6 months Timeline supported by previously filed 2017 MAA and 2012 NDA Team working since January to prepare key components of the NDA

  17. Slide 17: Closing

    Closing Michael Bailey, President and Chief Executive Officer

  18. Slide 18: Significant Potential Commercial Opportunity for Tivozanib in the United States

    Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market ~$1B1 2st Line Market ~$700M1 3rd Line+ Market ~$300M1 Expanding opportunity Potential to be first agent indicated for 3rd & 4th line Only pivotal dataset in RCC stratified by prior PD-1 NA Royalties to K

  19. Slide 19: FOTIVDA (tivozanib) Pillar Strategy

    FOTIVDA® (tivozanib) 3 Pillar Strategy MAA Review 2016 2017 2018 2019 2020 Ph 2 Expansion Ph 1 Data Ph 1 Tivo + Opdivo® EU Approval Potential RCC Ph 3 Randomized Combination Study Ph 2 Data EU Launch Country Level Reimbursement UK IT DE FR ES Composition of matter patent into 2022 with potential for

  20. Slide 20: Phase 1/2 Data Presented at ESMO in October 2018

    Phase 2 Data Presented at ESMO in October 2018 Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks N = 6 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q2 weeks Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240mg Q2 weeks Phase 1 Phase 2 N =

  21. Slide 21: Q&A

    Q&A

AVEO Pharmaceuticals — Corporate Update (November 2018) on 6ix